The UK and US have finalized a significant commercial pact that will guarantee no import taxes on British pharmaceutical exports being sold in the American market.
The Terms of the Pact
In exchange for the tariff guarantee, the UK has agreed to increase spending on medicines through the public health system. This move secures that import taxes on these key products will remain at zero for a period of three years.
This deal is in response to earlier statements to hike tariffs on branded pharmaceutical products, with increases floated reaching 100%.
"This agreement with the United Kingdom strengthens the international landscape for new treatments and establishes long-overdue fairness to U.S.–U.K. pharmaceutical trade," a statement said.
Trade Significance
Medicines are one of the Britain's most significant export categories to the US, which is clearly the biggest market for major companies like GSK and AstraZeneca.
Statistics show that in the one-year period to the end of the third quarter, the UK shipped pharmaceutical products totaling £11.1bn to the US. This figure made up 17.4% of all goods exports in that span.
"This deal protects jobs, increases capital expenditure and facilitates the UK to establish itself as a worldwide center for life sciences," the Business and Trade Secretary commented.
Specific UK Commitments
The agreement involves several specific pledges from the British government:
- Revised Affordability Limit: The UK will raise the cost ceiling at which it judges new therapies to be too expensive by 25%.
- Higher Drug Budget: There is a goal to raise overall public funding on drugs from 0.3% of Gross Domestic Product to 0.6% over the next decade.
- Payback Limit: The sum drug companies must pay back to the NHS to prevent overspending will be capped at fifteen percent. Previously, repayments topped 20%.
Broader Context
The pact follows a protracted row between the pharmaceutical industry and the UK government over spending levels and regulatory access.
The disagreement were heightened by claims that American customers were charged several times more for the identical medicines than consumers in the Britain and the EU.
Over the last 18 months, several major pharmaceutical investments in the UK have been halted or abandoned, while multi-billion-dollar funding commitments have been directed toward US facilities.
A senior figure publicly accepted that the NHS needed to invest a greater share on drugs, noting that its budget allocation on drugs had decreased as a proportion of its overall budget over the previous ten-year period.
